Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02581137
Other study ID # NCI-2015-01733
Secondary ID NCI-2015-01733HH
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date June 10, 2016
Est. completion date December 22, 2024

Study information

Verified date December 2023
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase IIa trial studies how well metformin hydrochloride works in preventing oral cancer in patients with an oral premalignant lesion (oral leukoplakia or erythroplakia). Oral premalignant lesions look like red or whitish plaques or lesions in the mouth that do not rub off and can be associated with a higher risk of cancer. Metformin hydrochloride may help prevent oral cancer from forming in patients with an oral premalignant lesion.


Description:

PRIMARY OBJECTIVES: I. To determine the clinical response of oral premalignant lesions to 12-14 weeks of metformin (metformin hydrochloride) intervention. SECONDARY OBJECTIVES: I. Histologic response to metformin intervention in the target lesion. II. Tissue-based biomarkers: metformin effect on cell proliferation and its molecular targets in the target lesion and in the normal tissue (marker of cell proliferation, Ki67, molecular targets of metformin, including, in order of priority, phosphorylated ribosomal protein S6 kinase [pS6], phosphorylated v-akt murine thymoma viral oncogene homolog 1 [pAKT]S473, phosphorylated eukaryotic translation initiation factor 4E-binding protein 1 [p4EBP], phosphorylated acetyl-CoA carboxylase alpha [pACC]). III. Tissue-based biomarkers: expression of dysregulated molecular mechanisms and organic cation transporter 3 (OCT 3) in the target lesion and in the normal tissue, including, in order of priority, epidermal growth factor receptor (EGFR), phosphorylated (p)EGFR, tumor protein 53 (p53), phosphatase and tensin homolog (PTEN), phosphorylated mitogen-activated protein kinase 1 (pERK), cyclin-dependent kinase inhibitor 2A (p16), and OCT3. IV. Tissue-based biomarkers: targeted analysis of cancer-associated genes in the target lesion and blood deoxyribonucleic acid (DNA). V. Serum and saliva based biomarkers: metformin effect on serum metabolic markers (C-peptide, glycosylated hemoglobin [HbA1c]). VI. Serum and saliva based biomarkers: metformin concentrations in serum and saliva. VII Serum and saliva based biomarkers: metformin effect on serum and saliva inflammatory and angiogenic cytokines, including interleukin (IL)-6, IL-8, growth-related oncogene-1 (GRO-1), and vascular endothelial growth factor (VEGF). EXPLORATORY OBJECTIVES: I. To characterize changes in the saliva microbiome before and after metformin intervention, including both the absolute microbial load and taxonomic composition. II. To evaluate the potential microbiome signatures that are correlated with treatment response. OUTLINE: Patients receive extended-release metformin hydrochloride orally (PO) once daily (QD) for 2 weeks and then twice daily (BID) for 10-12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 2-4 weeks.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 26
Est. completion date December 22, 2024
Est. primary completion date October 12, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participants with oral leukoplakia or erythroplakia with mild, moderate, or severe histologic dysplasia, or hyperplasia not associated with mechanical factors such as ill-fitted dentures - Measurable disease - minimum lesion size of 8 x 3 mm before initial biopsy - Karnofsky performance status >= 70% - Leukocytes >= 3,000/microliter - Absolute neutrophil count >= 1,000/microliter - Platelets >= 100,000/microliter - Total bilirubin =< 1.5 × institutional upper limit of normal (ULN) - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =<1.5 × institutional ULN - eGFR > 40 mL/min using the Cockcroft-Gault equation - Life expectancy > 3 months - Willing to use adequate contraception (barrier method, abstinence, subject has had a vasectomy or partner is using effective birth control or is postmenopausal) for the duration of study participation - Ability to take oral medication - Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: - Patients with diabetes who are taking insulin or oral agents - History of diabetic ketoacidosis - Participants may not be receiving any other investigational agents within past 3 months - History of allergic reactions attributed to compounds of similar chemical composition to metformin or prior use of metformin within the last year - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, human immunodeficiency virus (HIV)-positive, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Oral carcinoma in situ - History of chronic alcohol use or abuse defined as any one of the following: a) average consumption of 3 or more alcohol containing beverages daily in the past 12 months; b) consumption of 7 or more alcoholic beverages within a 24 hour (hr) period in the past 12 months - Glycated hemoglobin (HbA1c) > 8% - Pregnancy or nursing women - Acute or chronic liver disease, evidence of hepatitis (infectious or autoimmune), cirrhosis or portal hypertension - History of renal disease - History of prior head and neck squamous cell carcinoma (HNSCC) unless curatively treated for >= 1 year - Have received chemotherapy and/or radiation for any malignancy (excluding non-melanoma skin cancer and cancers confined to organs with removal as only treatment) in the past 2 years; ongoing adjuvant hormonal therapy for breast cancer is allowed

Study Design


Intervention

Other:
Laboratory Biomarker Analysis
Correlative studies
Drug:
Metformin Hydrochloride
Given PO

Locations

Country Name City State
Canada BC Cancer Research Centre Vancouver British Columbia
Canada University of British Columbia Hospital Vancouver British Columbia
United States University of Minnesota/Masonic Cancer Center Minneapolis Minnesota
United States UC San Diego Medical Center - Hillcrest San Diego California

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in Saliva Microbiome Analyzed Using Flow Cytometry This will characterize changes in the saliva microbiome before and after metformin intervention, including both the absolute microbial load and taxonomic composition. Will first evaluate changes in alpha diversity among matched pairs using non-parametric analogous Wilcoxon rank-sum test (Mann-Whitney test). To test for significant differences in beta diversity (e.g. if pretreatment and post-treatment samples cluster in principle coordinates analysis space), permutational multivariate analysis of variance (PERMANOVA) will be used. Baseline to up to 14 weeks
Other Microbiome Signatures Correlated With Treatment Response Will first evaluate changes in alpha diversity among matched pairs using non-parametric analogous Wilcoxon rank-sum test (Mann-Whitney test). To test for significant differences in beta diversity (e.g. if pretreatment and post-treatment samples cluster in principle coordinates analysis space), PERMANOVA will be used. Baseline to up to 14 weeks
Primary Clinical Response to Metformin Intervention Number of participants with complete and partial clinical response to metformin intervention.
Criteria for complete and partial clinical response are:
Complete Response (CR): Disappearance of all evidence of lesion(s). Partial Response (PR): Greater than or equal to 50% reduction in the sum of the products of diameters of lesion(s) measurable at baseline. Non-measurable lesion(s) may not increase greater than or equal to 25% in size and no new lesion may appear.
Baseline to up to 14 weeks
Secondary Histologic Response to Metformin Intervention Number of participants with complete and partial histologic response to metformin intervention.
Criteria for complete and partial histologic response are:
Complete Response (CR): Complete reversal of dysplasia or hyperplasia to normal epithelium in the target lesion.
Partial Response (PR): Improvement of the degree of dysplasia or hyperplasia in the target lesion.
Baseline to up to 14 weeks
Secondary Changes in Cell Proliferation and Its Molecular Targets Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers. Baseline to up to 14 weeks
Secondary Changes in Frequent Dysregulated Molecular Mechanisms and OCT Expression Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers. A univariate logistic regression model with the clinical response as the outcome variable will be fitted to explore if any of the expression of frequent dysregulated mechanisms and OCT3 level are associated with the clinical response to metformin hydrochloride. Baseline to up to 14 weeks
Secondary Impact of Genomic Alterations on the Biological and Biochemical Consequences and Clinical Response to Metformin Hydrochloride Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers. A univariate logistic regression model with the clinical response as the outcome variable will be fitted to explore if any genomic alterations are associated with the clinical response to metformin hydrochloride. Up to 14 weeks
Secondary Change in Measurements of Metformin Hydrochloride Concentrations in Serum and Saliva Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers. Baseline to up to 14 weeks
Secondary Change in Serum Metabolic Markers Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers. Baseline to up to 14 weeks
Secondary Change in Serum and Saliva Inflammatory and Angiogenic Cytokines Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers. Baseline to up to 14 weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT05505539 - Intralesional 5-fluorouracil Injection for the Treatment of Oral Leukoplakia Phase 1
Terminated NCT00176566 - A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia Phase 2
Completed NCT03682562 - Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
Completed NCT04153266 - Oral Epithelial Dysplasia Informational Needs Questionnaire
Completed NCT04712929 - Candida Associated Cytokines in Oral Leukoplakia
Completed NCT03031899 - Comparison or Rose Bengal and Toluidine Blue Staining for Lesion Detection Efficacy
Terminated NCT00571558 - Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia Phase 1
Recruiting NCT06321003 - SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography
Not yet recruiting NCT04732741 - Diagnostic Accuracy of Salivary Gamma-synuclein in Oral Malignant and Premalignant Lesions
Completed NCT00369174 - Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia Phase 2
Completed NCT00099021 - Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia Phase 2
Not yet recruiting NCT05727761 - Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia Phase 2
Recruiting NCT05942794 - Identification of Oral Lesions Through an Autofluorescence System N/A
Completed NCT00330382 - Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Phase 2
Recruiting NCT05237960 - Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia Phase 2
Not yet recruiting NCT06256809 - Analyzing Handprint Patterns to Predict Oral Cancer Risks: A Comparative Study
Completed NCT00951379 - Pioglitazone for Oral Premalignant Lesions Phase 2
Recruiting NCT04251845 - Evaluation of Effect of Topical Melatonin in Treatment of Oral Leukoplakia N/A
Terminated NCT04079491 - Intra and Extra Oral Inspection of Oral Mucosa
Recruiting NCT00767442 - Least Invasive Nonlinear Light Microscopy N/A